Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics to improve the lives of patients with serious diseases. We have an industry-leading and differentiated drug discovery platform. Our comprehensive proprietary libraries of the extracellular proteome, differentiated screening capabilities and protein therapeutic generation and engineering capabilities comprise a unique and powerful IND engine that positions us to discover novel pathways and targets in immuno-oncology and will continue to generate important development programs. Our success with our drug discovery platform has led to a pipeline that is on track to more than double to five development programs in clinical trials across multiple indications in 2018. We also have several undisclosed research programs at different points of the target validation and molecule generation phases that have the potential to yield our next wave of development-stage therapeutic biologics. And we continue to fuel this process at the earliest stages with new screens planned this year.
Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
The company is in a strong financial position and has an effective executive team and Board of Directors. Discover more about Five Prime at www.fiveprime.com
Stock Symbol: FPRX
Stock Exchange: Nasdaq
245 articles with Five Prime Therapeutics, Inc.
Five Prime Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 8
Five Prime Therapeutics, Inc. will report its second quarter 2018 financial results on Wednesday, August 8, 2018
In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.
Cell Medica today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
Five Prime Therapeutics, Inc., today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Goldman Sachs 39th Annual Global Healthcare Conference.
Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at the 2018 ASCO Annual Meeting
Five Prime Therapeutics, Inc. announced that a poster titled “FIGHT: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 (mFOLFOX6) in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer with a Dose Finding Phase 1 Lead-In” was presented today at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Five Prime Therapeutics, Inc. announced that Francis Sarena, Chief Strategy Officer, will present at the Jefferies 2018 Global Healthcare Conference.
Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates
Five Prime Therapeutics, Inc. announced it has entered into a collaboration with Roche to develop immunohistochemistry (IHC) companion diagnostic assays for use with Five Prime’s first-in-class investigational drug candidates.
Five Prime Therapeutics, Inc. will join the Pancreatic Cancer Action Network (PanCAN) PurpleStride San Francisco.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
Cabiralizumab advanced into a randomized Phase 2 trial in pancreatic cancer
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
Five Prime Therapeutics, Inc. announced that it initiated patient dosing in its Phase 1 clinical trial of FPA150, a first-in-class immuno-oncology antibody that targets B7-H4.
Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced UCB has elected to exclusively license an undisclosed drug target for inflammatory diseases.
Five Prime Therapeutics, Inc. announced that Marc Belsky, Senior Vice President and Chief Financial Officer, has resigned to pursue another opportunity.
Five Prime Therapeutics, Inc. provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2017.
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Leerink Partners LLC are acting as book-running managers for the offering.
Five Prime Therapeutics Announces $25M Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer.
The offering is expected to close on January 29, 2018, subject to customary closing conditions.
Five Prime intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 15% of these shares of common stock offered in the public offering.